Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ABMD's Cash to Debt is ranked higher than
94% of the 393 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. ABMD: No Debt )
ABMD' s 10-Year Cash to Debt Range
Min: 31.75   Max: No Debt
Current: No Debt

Equity to Asset 0.83
ABMD's Equity to Asset is ranked higher than
87% of the 373 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ABMD: 0.83 )
ABMD' s 10-Year Equity to Asset Range
Min: 0.69   Max: 0.94
Current: 0.83

0.69
0.94
Interest Coverage No Debt
ABMD's Interest Coverage is ranked higher than
75% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: 155.33 vs. ABMD: No Debt )
ABMD' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 6
Z-Score: 16.74
M-Score: -2.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 4.28
ABMD's Operating margin (%) is ranked higher than
70% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 6.29 vs. ABMD: 4.28 )
ABMD' s 10-Year Operating margin (%) Range
Min: -111.48   Max: 10.46
Current: 4.28

-111.48
10.46
Net-margin (%) 3.88
ABMD's Net-margin (%) is ranked higher than
71% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 5.11 vs. ABMD: 3.88 )
ABMD' s 10-Year Net-margin (%) Range
Min: -84.54   Max: 9.5
Current: 3.88

-84.54
9.5
ROE (%) 4.65
ABMD's ROE (%) is ranked higher than
71% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 5.84 vs. ABMD: 4.65 )
ABMD' s 10-Year ROE (%) Range
Min: -46.87   Max: 11.4
Current: 4.65

-46.87
11.4
ROA (%) 3.85
ABMD's ROA (%) is ranked higher than
75% of the 393 Companies
in the Global Medical Devices industry.

( Industry Median: 3.49 vs. ABMD: 3.85 )
ABMD' s 10-Year ROA (%) Range
Min: -42.19   Max: 9.27
Current: 3.85

-42.19
9.27
ROC (Joel Greenblatt) (%) 40.29
ABMD's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 392 Companies
in the Global Medical Devices industry.

( Industry Median: 12.42 vs. ABMD: 40.29 )
ABMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -294.77   Max: 90.23
Current: 40.29

-294.77
90.23
Revenue Growth (%) 17.50
ABMD's Revenue Growth (%) is ranked higher than
92% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. ABMD: 17.50 )
ABMD' s 10-Year Revenue Growth (%) Range
Min: -7.2   Max: 26.3
Current: 17.5

-7.2
26.3
» ABMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ABMD Guru Trades in Q3 2013

Paul Tudor Jones 16,000 sh (New)
Steven Cohen 15,457 sh (+572.04%)
Jim Simons 260,523 sh (+97.03%)
PRIMECAP Management 5,751,990 sh (unchged)
» More
Q4 2013

ABMD Guru Trades in Q4 2013

PRIMECAP Management 5,751,990 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Jim Simons 79,323 sh (-69.55%)
» More
Q1 2014

ABMD Guru Trades in Q1 2014

Paul Tudor Jones 11,200 sh (New)
Steven Cohen 11,972 sh (New)
Joel Greenblatt 25,692 sh (New)
PRIMECAP Management 5,751,990 sh (unchged)
Jim Simons Sold Out
» More
Q2 2014

ABMD Guru Trades in Q2 2014

Chase Coleman 1,690,000 sh (New)
Jim Simons 97,223 sh (New)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 5,726,490 sh (-0.44%)
» More
» Details

Insider Trades

Latest Guru Trades with ABMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Sold Out 0.01%$20.87 - $26.2 $ 24.957%0
Joel Greenblatt 2014-03-31 New Buy0.01%$25.6 - $30.03 $ 24.95-10%25692
PRIMECAP Management 2011-06-30 Add 28.42%0.02%$14.65 - $18.94 $ 24.9548%3772973
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 135.30
ABMD's P/E(ttm) is ranked higher than
69% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 55.30 vs. ABMD: 135.30 )
ABMD' s 10-Year P/E(ttm) Range
Min: 36.46   Max: 946.92
Current: 135.3

36.46
946.92
P/B 5.90
ABMD's P/B is ranked higher than
56% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 3.41 vs. ABMD: 5.90 )
ABMD' s 10-Year P/B Range
Min: 1.58   Max: 7.69
Current: 5.9

1.58
7.69
P/S 5.50
ABMD's P/S is ranked higher than
59% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. ABMD: 5.50 )
ABMD' s 10-Year P/S Range
Min: 2.38   Max: 10.62
Current: 5.5

2.38
10.62
PFCF 43.20
ABMD's PFCF is ranked higher than
82% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABMD: 43.20 )
ABMD' s 10-Year PFCF Range
Min: 23.56   Max: 2462
Current: 43.2

23.56
2462
EV-to-EBIT 112.88
ABMD's EV-to-EBIT is ranked higher than
69% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 37.22 vs. ABMD: 112.88 )
ABMD' s 10-Year EV-to-EBIT Range
Min: 27   Max: 694.7
Current: 112.88

27
694.7
Current Ratio 4.39
ABMD's Current Ratio is ranked higher than
84% of the 391 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. ABMD: 4.39 )
ABMD' s 10-Year Current Ratio Range
Min: 3.18   Max: 15.95
Current: 4.39

3.18
15.95
Quick Ratio 3.91
ABMD's Quick Ratio is ranked higher than
86% of the 391 Companies
in the Global Medical Devices industry.

( Industry Median: 2.07 vs. ABMD: 3.91 )
ABMD' s 10-Year Quick Ratio Range
Min: 2.56   Max: 15.43
Current: 3.91

2.56
15.43

Valuation & Return

vs
industry
vs
history
Price/Net Cash 19.34
ABMD's Price/Net Cash is ranked higher than
88% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABMD: 19.34 )
ABMD' s 10-Year Price/Net Cash Range
Min: 1.29   Max: 73.96
Current: 19.34

1.29
73.96
Price/Net Current Asset Value 13.21
ABMD's Price/Net Current Asset Value is ranked higher than
83% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABMD: 13.21 )
ABMD' s 10-Year Price/Net Current Asset Value Range
Min: 1.16   Max: 409.4
Current: 13.21

1.16
409.4
Price/Tangible Book 7.52
ABMD's Price/Tangible Book is ranked higher than
62% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 5.89 vs. ABMD: 7.52 )
ABMD' s 10-Year Price/Tangible Book Range
Min: 1   Max: 16.93
Current: 7.52

1
16.93
Price/DCF (Projected) 4.79
ABMD's Price/DCF (Projected) is ranked higher than
80% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 17.20 vs. ABMD: 4.79 )
ABMD' s 10-Year Price/DCF (Projected) Range
Min: 4.72   Max: 41.45
Current: 4.79

4.72
41.45
Price/Median PS Value 0.89
ABMD's Price/Median PS Value is ranked higher than
83% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 1.15 vs. ABMD: 0.89 )
ABMD' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 4.3
Current: 0.89

0.38
4.3
Price/Graham Number 6.72
ABMD's Price/Graham Number is ranked higher than
70% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 6.47 vs. ABMD: 6.72 )
ABMD' s 10-Year Price/Graham Number Range
Min: 2.97   Max: 15.85
Current: 6.72

2.97
15.85
Earnings Yield (Greenblatt) 0.90
ABMD's Earnings Yield (Greenblatt) is ranked higher than
51% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. ABMD: 0.90 )
ABMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 3.7
Current: 0.9

0.1
3.7
Forward Rate of Return (Yacktman) 0.03
ABMD's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 1.34 vs. ABMD: 0.03 )
ABMD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3.8   Max: -0.2
Current: 0.03

-3.8
-0.2

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:AIO.Germany
Abiomed, Inc., is a Delaware corporation. The Company is a provider of mechanical circulatory support devices and it offers a continuum of care in heart recovery to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. Its products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. The Company's Impella 2.5 catheter is a percutaneous micro heart pump with an integrated motor and sensors for use mainly in interventional cardiology. The device is designed mainly for use by interventional cardiologists to support patients in the cath lab who may require assistance to maintain their circulation. The Impella 5.0 catheter and Impella LD are percutaneous micro heart pumps with integrated motors and sensors for use mainly in the heart surgery suite. These devices are designed to support patients who require higher levels of circulatory support as compared to the Impella 2.5. It manufactures and sells the AB5000 Circulatory Support System and the BVS 5000 Biventricular Support System for the temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. The Company's AbioCor Implantable Replacement Heart is the first completely self-contained artificial heart, designed to sustain the body's circulation, the AbioCor is intended for end-stage biventricular heart failure patients whose other treatment options have been exhausted. Its main competitors are Getinge, Teleflex Inc., Thoratec Corporation, HeartWare International Inc., Jarvik Heart, CircuLite, Inc., Terumo Heart, Inc. and CardiacAssist Inc. The Company is subject to extensive federal, state, local and foreign regulation.
» More Articles for ABMD

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Weekly CFO Sells Highlight: BDSI, LNKD, VRSK, ABMD, AGX Jul 17 2012 
ABIOMED Inc. Reports Operating Results (10-Q) Feb 04 2011 
ABIOMED Inc. Reports Operating Results (10-Q) Aug 05 2010 
ABIOMED Inc. (ABMD) COO David M Weber sells 1,389 Shares May 25 2010 
ABIOMED Inc. (ABMD) President, CEO, Chairman Michael R Minogue sells 4,491 Shares May 25 2010 
Trade Setups for May 19, 2010 May 19 2010 
Trade Setups for May 17, 2010 May 17 2010 
ABIOMED Inc. Reports Operating Results (10-Q) Feb 05 2010 

More From Other Websites
ABIOMED Up on Positive Impella RP Clinical Trial Results Sep 18 2014
Abiomed Appoints Ingrid Goldberg as Director of Investor Relations Sep 18 2014
Clinical Trial Results for Impella RP Right Ventricular Heart Failure Trial, RECOVER RIGHT, Released... Sep 16 2014
ABIOMED INC Files SEC form 8-K/A, Financial Statements and Exhibits Sep 12 2014
Data From RECOVER RIGHT Impella RP Trial to be Announced at TCT 2014 Sep 10 2014
French company Carmat fits second patient with artificial heart Sep 08 2014
Abiomed to Present at the Morgan Stanley Global Healthcare Conference 2014 Sep 03 2014
ABIOMED INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to... Aug 19 2014
ABIOMED INC Financials Aug 13 2014
ABIOMED INC Files SEC form 10-Q, Quarterly Report Aug 06 2014
Abiomed Falls, Sees Flat Fiscal Q1 Loss and Miss Estimates Aug 04 2014
ABIOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 31 2014
Q1 2015 Abiomed, Inc. Earnings Release - Before Market Open Jul 31 2014
Abiomed Announces First Quarter Fiscal 2015 Revenue of $48.8 Million, Up 14% Over Prior Year Jul 31 2014
Abiomed First Quarter Fiscal 2015 Earnings and Conference Call Notification Jul 16 2014
ABIOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of... Jul 07 2014
ABIOMED Acquires Germany's Medical Device Maker Jul 02 2014
Abiomed Announces Acquisition of ECP to Broaden and Strengthen Existing Intellectual Property and... Jul 01 2014
ABIOMED INC Files SEC form 8-K, Other Events Jun 11 2014
ABIOMED Impella Platform Crosses 20K Mark Jun 05 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK